Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLes inhibiteurs de l'enzyme de conversion dans le traitement de l'hypertension artérielle
Rorive, Georges ULg; Krzesinski, Jean-Marie ULg; Carlier, P. G.

in Revue Médicale de Liège (1988), 43(9), 321-326

Les inhibiteurs de l'enzyme de conversion nous donnent pour la première fois la possibilité d'inhiber l'activité du système rénine-angiotensine chez les patients hypertendus. Ces vasodilatateurs n ... [more ▼]

Les inhibiteurs de l'enzyme de conversion nous donnent pour la première fois la possibilité d'inhiber l'activité du système rénine-angiotensine chez les patients hypertendus. Ces vasodilatateurs n'entraînent ni tachycardie réflexe, ni rétention hydrosodée. Leur utilisation ne s'accompagne pas de modifications métaboliques mais certains effets secondaires (toux, altération de la fonction rénale), liés d'ailleurs au mode d'action, ont été relevés. Bien tolérés, ces dérivés peuvent être utilisés en monothérapie dans le traitement de l'hypertension légère, mais leur supériorité par rapport aux diurétiques et aux bêtabloquants dans la prévention des complications cardiovasculaires de l'hypertension reste à établir. [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique : que nous dit l'Evidence Based Medicine?
Krzesinski, Jean-Marie ULg; Montrieux, Christian ULg; Scheen, André ULg

in Revue Médicale de Liège (2006), 61(5-6), 414-422

Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor ... [more ▼]

Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor antagonists stand their excellent tolerance and the possible therapeutic escape seen with angiotensin converting enzyme inhibitors. For the preferential use of the latter, the arguments are the absence of a real proof of any superiority of the angiotensin receptor blockers and their higher cost. The wisdom is to initially use angiotensin converting enzyme inhibitors in secondary prevention excepted when they are not well tolerated. The large ONTARGET cardiovascular prevention trial should help solve this controversy. [less ▲]

Detailed reference viewed: 374 (4 ULg)
Full Text
Peer Reviewed
See detailLes inhibiteurs de l'enzyme de conversion: la molécule a-t-elle de l'importance?
Rorive, Georges ULg; Krzesinski, Jean-Marie ULg

in Médecine et Hygiène (1991), 49

De nombreuses, peut-être de trop nombreuses molécules, dotées d'un pouvoir d'inhibition de l'enzyme de conversion ont été introduites ces dix dernières années pour le traitement de l'hypertension ... [more ▼]

De nombreuses, peut-être de trop nombreuses molécules, dotées d'un pouvoir d'inhibition de l'enzyme de conversion ont été introduites ces dix dernières années pour le traitement de l'hypertension artérielle et de l'asystolie. Les différences entre ces molécules sont peu importantes et sont fonction de leur structure moléculaire. Le captopril, seul dérivé doté d'un groupe sulfhydrile, a un effet rapide et de durée assez brève; son utilisation s'accompagne par ailleurs de certains effets secondaires propres au groupe SR. Par contre, le délai d'action des dérivés dont le ligand est un groupe carboxyle est généralement plus tardif, leur durée d'action plus longue, justifiant une prise par jour. Il reste difficile d'affirmer que le groupe SR confère des propriétés cardioprotectrices plus importantes que celles dont jouissent les autres molécules de cette classe thérapeutique. De la même manière, à ce stade, les différences démontrées concernant la diffusion tissulaire des inhibiteurs de l'enzyme de conversion n'ont pas pu être illustrées par des observations cliniques. [less ▲]

Detailed reference viewed: 13 (0 ULg)
Full Text
See detailLes inhibiteurs de l'enzyme de conversion: leur place dans le traitement de l'hypertension artérielle
Rorive, Georges ULg; Krzesinski, Jean-Marie ULg; Carlier, P. G.

in Traité de Médecine Générale (1987)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs de la monoamine oxydase et anesthésie
Blom-Peters, L.; Larbuisson, Robert ULg; Lamy, Maurice ULg

in Revue Médicale de Liège (1988), XLIII(2), 51-56

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailLes inhibiteurs de la PSCK9: une innovation majeure dans le traitement des dyslipidémies ?
PAQUOT, Nicolas ULg

in ABD- le supplément du médecin (2014), 57(6), 6-7

Detailed reference viewed: 35 (3 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2
SCHEEN, André ULg; RADERMECKER, Régis ULg; ERNEST, Philippe ULg et al

in Revue Médicale Suisse (2011), 7(306), 1621-1629

Detailed reference viewed: 43 (11 ULg)
Full Text
See detailLes inhibiteurs du cotransporteur du glucose SGLT rénal: une nouvelle classe thérapeutique dans le diabète de type 2
Sepulchre, Edith; RADERMECKER, Régis ULg

in Journal de Cardiologie [= JDC] = Tijdschrift voor Cardiologie [= TVC] (2013), 25(8), 429-434

Detailed reference viewed: 103 (2 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT2 renal pour traiter le diabete de type 2.
SCHEEN, André ULg; Radermecker, Régis ULg; Ernest, P. et al

in Revue medicale suisse (2011), 7(306), 1621-41626-9

Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete ... [more ▼]

Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete glucose in urine when hyperglycaemia exceeds tubular reabsorption threshold. Such reabsorption depends on sodium-glucose cotransporters-2 (SGLT2), which can be blocked by selective inhibitors. These pharmacological agents augment glucosuria and reduce hyperglycaemia independently of insulin. Some have already proven their efficacy to improve glucose control, in monotherapy or in combination, while promoting weight loss and without inducing hypoglycaemia. Dapagliflozin should be the first medication of this new pharmacological class to be commercialized for the management of type 2 diabetes. [less ▲]

Detailed reference viewed: 16 (2 ULg)
Peer Reviewed
See detailInhibiteurs potentiels de proteases à sérine apparentés aux antibiotiques β-lactamiques
Pirotte, Bernard ULg; Vilain, A.-C.; Vergely, I. et al

in Regard sur la Biochimie (1991), 6, 91

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailInhibiting Effect of Ammonia on Citric Acid-Induced Cough in Pigs: A Possible Involvement of Substance P
Moreaux, B.; Nemmar, A.; Beerens, Dominique ULg et al

in Pharmacology & Toxicology (2000), 87(6), 279-285

The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed. For a period from one to four days, piglets were exposed, in an ... [more ▼]

The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed. For a period from one to four days, piglets were exposed, in an inhalation chamber, to ammonia at a concentration of 15 or 30 ppm. During exposure, cough induction tests were done every two days. Recovery of the cough reflex after ammonia exposure was also determined. In a separate group of piglets exposed for 2 days to 30 ppm ammonia, substance P content was determined in bronchial and tracheal lavage fluids and in the tracheal and bronchial mucosa. Ammonia (30 ppm) was found to inhibit coughing significantly (the cough frequency was reduced by 64%) after a two-day exposure. In animals exposed for 4 days to this ammonia concentration, the recovery ranged from 3 to 7 days (mean: 5 days). The same ammonia concentration also caused the substance P content to increase significantly in bronchoalveolar lavage fluid (to 432% of its initial value) and tracheal lavage fluid (to 149%) and to decrease significantly in the tracheal mucosa (-58%), however the content in bronchial mucosa was not significantly affected (-43%). Exposure to 15 ppm ammonia had no effect on the frequency of citric acid-induced coughing. In conclusion, ammonia inhibits citric acid-induced coughing in pigs at concentrations that can be detected in piggeries. This inhibitory effect may be related to substance-P depletion in C-fiber endings [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailInhibiting or Antagonizing Glucagon: A Progress in Diabetes Care ?
LEFEBVRE, Pierre ULg; Paquot, Nicolas ULg; Scheen, André ULg

in Diabetes, obesity & metabolism (2015)

Absolute or relative hyperglucagonemia has been recognized for years in all experimental or clinical forms of diabetes. It has been suggested that excess secretion of glucagon by the islet alpha-cells is ... [more ▼]

Absolute or relative hyperglucagonemia has been recognized for years in all experimental or clinical forms of diabetes. It has been suggested that excess secretion of glucagon by the islet alpha-cells is a direct consequence of intra-islet insulin secretory defects. Recent studies have demonstrated that knock-out of the glucagon receptor or administration of a monoclonal specific glucagon receptor antibody make insulin deficient type 1 diabetic rodents thrive without insulin. These observations suggest that glucagon plays an essential role in the pathophysiology of diabetes and that targeting the alpha-cell and glucagon are innovative approaches in the management of diabetes. Despite active research and identification of promising compounds, no one selective glucagon antagonist is presently used in the treatment of diabetes. Interestingly, besides insulin, several drugs used today in the management of diabetes appear to exert their effects in part by inhibiting glucagon secretion (GLP-1 receptor agonists, DPP-4 inhibitors, alpha glucosidase inhibitors and, maybe, sulfonylureas) or glucagon action (metformin). The potential risks associated with total glucagon suppression include alpha-cell hyperplasia, increased mass of the pancreas, increased susceptibility to hepatosteatosis and hepatocellular injury and increased risk of hypoglycaemia and should be considered in the search and development of new compounds reducing glucagon receptor signalling. In conclusion, more than 40 years after its initial description, the hyperglucagonemia of diabetes can no longer be ignored or minimized and its correction represents an attractive way for improving diabetes management. [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailInhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2
Brown, JP; McClung, MR; Grauer, A et al

in Revue du Rhumatisme (2013), 80(S1), 73

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailInhibition des recepteurs CB1 et metabolisme du glucose: rimonabant dans le diabete de type 2.
Scheen, André ULg; Paquot, Nicolas ULg; Van Gaal, Luc F

in Revue Médicale Suisse (2008), 4(168), 1812-7

Endocannabinoid system is overactivated in individuals with abdominal obesity. CBI receptors, first individualized in the brain, are also expressed in the adipocyte, the skeletal muscle, the liver, the ... [more ▼]

Endocannabinoid system is overactivated in individuals with abdominal obesity. CBI receptors, first individualized in the brain, are also expressed in the adipocyte, the skeletal muscle, the liver, the gut, and the pancreas. Their blockade improves glucose tolerance and lipid profile, thanks increased insulin sensitivity and adiponectin levels. Rimonabant, a selective antagonist of CBI receptors, improves glucose control in patients with type 2 diabetes, treated with diet alone, metformin, sulfonylurea or insulin, while it also reduces body weight and other risk factors. Ongoing studies aim at further demonstrating the potential of rimonabant in the management of type 2 diabetes, in the prevention of type 2 diabetes and in the protection against cardiovascular complications in (diabetic) patients with abdominal obesity. [less ▲]

Detailed reference viewed: 62 (3 ULg)
See detailInhibition et lobes frontaux
Le Gall, Didier; Van der Linden, Martial ULg; Andrès Bénito, Pilar et al

in Boujon, C. (Ed.) L'inhibition au carrefour des neurosciences et des sciences de la cognition : fonctionnements normal et pathologique (2002)

Detailed reference viewed: 60 (7 ULg)